Argenx’s Autoimmune Disease Blockbuster-In-Waiting Gets FDA Decision Date

Myasthenia Gravis Is First Target

 
• By Andrew McConaghie
  
Myasthenia gravis
Myasthenia gravis causes muscle weakness, typically affecting the eyes and face.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip